In a related commentary in the same issue, Mark S. Talamonti, MD, of the NorthShore University HealthSystem, wrote, "With an aging population, this most formidable of human cancers will only increase in incidence and frequency. There is a clear and unequivocal need for affordable screening strategies based on reliable biomarkers and efficient imaging modalities."
A magnetic resonance imaging (MRI)-based screening program for individuals at high risk of pancreatic cancer identified pancreatic lesions in 16 of 40 (40%) of patients, of whom 5 underwent surgery, according to a report published online by JAMA Surgery.
Pancreatic cancer is a leading cause of cancer death and can be considered a global lethal disease because incidence and mortality rates are nearly identical. Although treatment has improved, the surgery rate in patients with ductal adenocarcinoma is around 30% and the 5-year survival rate is less than 20%. In about 10% of all patients with pancreatic cancer, it is possible to find a family history, according to the study background.
Marco Del Chiaro, MD, PhD, of the Karolinska Institute, Stockholm, Sweden, and coauthors analyzed short-term results from an MRI-based screening program for patients with a genetic risk of developing pancreatic cancer.
Complete report on EurekAlert!:
http://bit.ly/1GsGaEw
Read the paper in JAMA Surgery:
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More